Announcements

VGI Health Technology Limited further updates Sunset Date for sale of Invictus BioPharma Pty Ltd - 26 June 2023

VGI Health Technology Limited - Change of Registered Office - 26 June 2023

NSX Quarterly Report for the period ending 31 March 2023 - 19 April 2023

VGI Health Technology Limited further updates Sunset Date for sale of Invictus BioPharma Pty Ltd - 3 April 2023

Interim Report for the half year ended 31 December 2022 - 16 February 2023

NSX Quarterly Report 31 December 2022 - 31 January 2023

Click here for the announcement

Click here for the quarterly report

VGI Health Technology Limited further updates Sunset Date for sale of Invictus BioPharma Pty Ltd - 21 December 2022

VGI Health Technology Limited - Company Update - 21 December 2022

VGI Health Technology Limited - Update on NAFLD/NASH Phase II Clinical Study - 19 December 2022

Results of 2022 Annual General Meeting - 30 November 2022

Extension of Sunset Date for sale of Invictus BioPharma Pty Ltd - 29 November 2022

Update to sunset date for sale of subsidiary Invictus Biopharma Pty Ltd - 26 October 2022

VGI Health Technology Limited Proxy Form for 2022 Annual General Meeting - 25 October 2022

VGI Health Technology Limited 2022 Annual General Meeting - 25 October 2022

VGI Health Technology - Sept 2022 Quarterly Update - 19 October 2022

VGI Health Technology Limited - Sept Quarterly Report - 19 October 2022

VGI Health Technology extends term of convertible note facility - 14 October 2022

VGI Health Technology Limited enters into R & D Loan Facility Agreement with Fundsquire Pty Ltd - 13 October 2022

NAFLD/NASH Phase II Clinical Study commences dosing patients - 5 October 2022

Ethics Approval Received for US Pharmacokinetics and Exercise Clinical Study - 26 September 2022

VGI Health Technology Limited – Phase II Clinical Study in NAFLD Recruits First Patient - 14 September 2022

VGI Health Technology Limited – Annual Report for the year ended 30 June 2022

VGI Health Technology Limited – Quarterly Cashflow Report for June 2022 - 29 July 2022

VGI Health Technology Limited – Quarterly Update for June 2022 - 29 July 2022

VGI Health Technology Limited – NAFLD/NASH Phase II Clinical Study begins recruitment of patients - 5 July 2022

Results of Special General Meeting held 3 June 2022 - 3 June 2022

Extraordinary General Meeting of Shareholders - 3 May 2022

Update for the period ending 31 March 2022 - 29 April 2022

Click here for the announcement

Click here for the signed quarterly report

US Divisional Patent to be granted for Transmucosal Delivery of Tocotrienols - 4 April 2022

Dr Jordan Moon to present at American Society for Nutrition Conference - 21 March 2022

VGI Health Technology executes Sales Representative Agreement with Continuum Sciences LLC - 25 February 2022

VTL's Dr Jordan Moon to present at Experimental Biology Conference in Philadelphia - 23 February 2022

VGI Health Technology executes Term Sheet for sale of the Invictus BioPharma Group - 14 February 2022

Approval for new NAFLD/NASH Phase II clinical study site at the Gallipoli Medical Research Foundation in Queensland - 9 February 2022

Hong Kong Patent Granted to VTL subsidiary Invictus Biotechnology Pty Ltd - 8 February 2022

VGI Health Dec '21 Quarterly Cashflow Report - 27 January 2022

VTL contracts with Resonance Health for its NASH Phase II Clinical Study - 25 January 2021

VGI Health Technology's NE1-Elite® and NE1-Heart® nutraceutical products listed on Amazon - 20 January 2022

Quarterly update for December 2021 quarter - 18 January 2022

VTL PCT Patent Application on Transmucosal Delivery of Tocotrienols - 7 December 2021

VTL Partnership with ENDRA Life Sciences in NASH Clinical Study - 29 November 2021

VTL announces results of 2021 Annual General Meeting - 17 November 2021

VTL September 2021 Quarterly Cashflow Report - 29 October 2021

Japanese patent to be granted for Transmucosal Delivery of Tocotrienols - 18 October 2021

40560 NSX Quarterly Report - Quarterly update - 8 October 2021

HREC Approval received from The Royal Melbourne Hospital for NAFLD/NASH study - 6 October 2021

VTL draws down on $1.5M convertible loan facility with Cornerstone Investor - 5 October 2021

VGI Health Technology issues FY21 Annual Report to Shareholders - 22 September 2021

Notice of Annual General Meeting and Proxy Form - 22 September 2021

VTL appoints Professor Darrell Crawford to Scientific Advisory Board - 15 September 2021

VTL appoints Gallipoli Medical Research Foundation as NAFLD/NASH Clinical Study Site - 14 September 2021

VTL approves study protocol for NE1-Elite® clinical study in US - 13 September 2021

VGI Health Technology 2021 Statutory Financial Statements - 8 September 2021

VGI Health Technology renews R & D Receivables Facility with FIFO Capital for Financial Year 2022 - 7 September 2021

VGI Health Technology's NE1-Elite(r) sports nutraceutical product certified by Informed Sport - 12 August 2021

NSX Quarterly Report - June 2021 Quarterly Report - 2 July 2021

NSX General Market Disclosure Other - Shareholder update - 13 July 2021

VGI Health Technology Limited (formerly Azure Health Technology Limtied) (the Company or VTL) is pleased to advise, following shareholder approval obtained On Friday 9 July, that the Company’s name has officially changed with the Australian Securities and Investments Commission - 12 July 2021.

VGI Health Technology (NSX:VTL) receives finished nutraceutical products in the US - 15 June 2021

Change in substantial shareholder notice for VGI Big Bang Pty Ltd - 8 June 2021

Pitt Street Research issues Initiation Report on Azure Health Technology Limited trading as VGI Health Technology (NSX:VTL) - 8 June 2021

Azure Health Technology Limited trading as VGI Health Technology appoints additional cGMP Manufacturer in US - 7 June 2021

40920 NSX Notice of Extraordinary Meeting - Extraordinary General Meeting - 4 June 2021

Extraordinary general meeting to change name of company and approve NSX compliant constitution.

Click here to download the proxy form.

Azure Health Technology Limited - Application for Quotation of Additional Securities - June 2021

Azure Health Technology Limited trading as VGI Health Technology commences trading on National Stock Exchange - 28 May 2021

Azure Health Technology Limited trading as VGI Health Technology approved to list on National Stock Exchange - 19 May 2021

Close of IPO and Name Change to VGI Health Technology Limited - 20 April 2021

Extension of Closing Date for IPO - 01 April 2021

Azure Health Technology Limited completes first manufacturing run in the US for nutraceutical products - 16 Mar 2021

AZT Announcement Replacement Prospectus and Opening of IPO - 5 Mar 2021

AZT Announcement Board Changes - 25 Feb 2021

AZT Press Release Malaysian Patent Granted - 25 Feb 2021

AZT IPO Proposed Capital Raise - 19 Feb 2021

ACCESS China Forum - An Introduction to Azure Health Technology Limited (AZT) - 21 Jan 2021

Brazilian Patent Application approved for granting - 19 Jan 2021

Azure Health Technology Limited's nutraceutical products listed on Australia's Therapeutic Goods Administration's (TGA"s) Australian Register of Therapeutic Goods (ARTG) as Listed Complementary Medicines - 18 Jan 2021

Capital Raising Update - 08 Dec 2020

Azure Health Technology Limited lodges new Australian Provisional Patent Application on Transmucosal Delivery of Tocotrienols - 07 Dec 2020

Listing Update

How to Vote Announcement

2020 AGM NOM and Proxy

2020 AGM Shareholder Q&A

Annual Report for the year ended 30 June 2020

Chinese Patent Application Granted for Transmucosal Delivery of tocotrienols - 01 October 2020

Board and Management Changes - 28 September 2020

Canadian Patent Office issues Notice of Allowance for Canadian Patent Application - 24 September 2020

Azure Health Technology completes study protocol for Pancreatic Cancer Phase II clinical study - 21 September 2020

Azure Health Technology Limited commences first manufacturing run in the US for nutraceutical products - 24 August 2020

Azure Health Technology Completes study protocol for NAFLD/NASH Phase II clinical study - 31 July 2020

Azure Health Technology Limited appoints Non-Executive Director - 02 July 2020

Azure Health Technology Limited commences preparations for pancreatic cancer Phase II clinical study - 22 June 2020

Azure Health Technology Limited commences preparations for NAFLD/NASH Phase II clinical study - 15 June 2020

Azure Health Technology Limited acquires Invictus BioPharma Limited - 11 June 2020

Azure Health Technology Limited successfully completes Capital Raise - 03 June 2020